Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2026-27/51

August 06, 2026

To, The Secretary **BSE Limited** Department of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Secretary **National Stock Exchange of India Limited** Corporate Communication Department, Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 051
Scrip Code - 532523	**Scrip Symbol - BIOCON**

Dear Sir/Madam,

Subject: Presentation – Q1 FY27 Earnings Call

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the presentation w.r.t. Q1 FY27 Earnings Call to be conducted on August 06, 2026.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record.

Thanking You,

Yours faithfully,

For **Biocon Limited**

RAJESH UMAKANT SHANOY
Digitally signed by RAJESH UMAKANT SHANOY
Date: 2026.08.06 07:17:27 +05'30'

Rajesh U. Shanoy
Company Secretary and Compliance officer
ICSI Membership Number: A16328

Enclosed: as above

SCIENCE FOR PEOPLE
ADVANCING IMPACT

Biocon

Biocon Limited
Q1 FY27 Earnings Call

06 – Aug – 2026

Safe Harbor Statement

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Chairperson's Opening Remarks

Positioned for the Next Phase of Growth

- **Integrated platform, global scale and resilient supply networks position Biocon for sustained growth**
- **North America: largest strategic market, policy tailwinds and launch execution**
  - Affordability and access remain central to policy dialogue
  - Recent US commercialization: Yesafili™ (bAflibercept), Bosaya™ & Aukelso™ (bDenosumab), gLiraglutide
  - Regional supply network strengthened through local capabilities and strategic partnerships
- **Europe: integrated portfolio in a well-established biosimilars and generics market**
  - Combined portfolio of 11 biosimilars and eight generic medicines
  - Tailored retail and tender strategies
  - Evfraxy® (bDenosumab) and Abevmy® (bBevacizumab) launches across select markets
- **Emerging Markets: access led growth through portfolio breadth and partnerships**
  - Broader portfolio with expanded commercial capabilities
  - Local partnerships, CMOs and technology-transfer initiatives
  - Yesafili™ launch in Malaysia; continued bevacizumab leadership in Brazil

Financial Highlights – Q1 FY27

Financial Highlights – Q1 FY27

In ₹ Cr	Q1 FY27	Q1 FY26	Q4 FY26	YoY%	QoQ%
Biopharmaceuticals					
- Biosimilars	2,855	2,458	2,756	*16*	*4*
- Generics	760	630*	776*	21	(2)
Services	736	875	1,037	*(16)*	*(29)*
Revenue from Operations	**4,336**	**3,942**	**4,517**	***10***	***(4)***
Total Revenue	4,391	4,022	4,569	*9*	*(-4)*
R&D (Net)	**240**	**205**	**277**	***17***	***(13)***
% of Revenue (Ex. Syngene)	*7*	*7*	*8*		
EBITDA	**902**	**846**	**1,073**	***7***	***(16)***
% Margin	*21*	*21*	*23*		
Profit Before Tax (Before exceptional items)	**141**	**114**	**328**	***24***	***(57)***
% Margin	*3*	*3*	*7*		
Net Profit (Before exceptional items)	**145**	**42**	**179**	***245***	***(19)***
Exceptional item, net of tax & NCI	(4)	(11)	(53)		
Net Profit (Reported)	**141**	**31**	**126**	***355***	***12***

** Excluding cross charge of common utilities that was earlier included within Generics but is now appropriately included under "Unallocable expenditure/(income)"*

Biosimilars

Biosimilars: Q1 FY27 Business Performance Update

- Financial Performance
  - Growth led primarily by North America market
  - EBITDA up 10% YoY, 25% EBITDA margin
  - R&D spend at 7% of revenue
- Growth momentum expected to build progressively through FY27, H2 to be meaningfully better
- Recent launches and market access progress provide visibility on a stronger second half
- EMA approval for second insulin drug product line in Malaysia doubles capacity and supports future growth

In ₹ Cr	Q1 FY27	Q1 FY26	Q4 FY26	YoY%	QoQ%
Segment Revenue	2,855	2,458	2,756	*16*	*4*
R & D	192	134	188	*44*	*2*
% of Revenue	*7%*	*5%*	*7%*		
EBITDA	728	662	720	*10*	*1*
% of Revenue	*25%*	*27%*	*26%*		

Generics

Generics: Q1 FY27 Business Performance Update

- Financial Performance
  - Revenues up 21% YoY
  - EBITDA margin up by over 250bps QoQ
  - R&D spend at 6% of revenue
- Generic liraglutide was a key driver across multiple markets, including the USA
- Margin improvement driven by operating leverage and cost efficiency initiatives
- Peptides, fermentation and manufacturing investments provide a strong platform for utilization-led margin expansion

In ₹ Cr	Q1 FY27	Q1 FY26*	Q4 FY26*	YoY%	QoQ%
Segment Revenue	760	630	776	*21*	*(2)*
R & D	47	70	89	*(33)*	*(47)*
% of Revenue	*6%*	*11%*	12%		
EBITDA	56	(35)	39	*nm*	*44*
% of Revenue	*7%*	*(6)%*	5%		

** Excluding cross charge of common utilities that was earlier included within Generics but is now appropriately included under "Unallocable expenditure/(income)"*

Services

Services: Q1 FY27 Business Performance Update

- **Financial Performance**
  - Performance impacted by lower offtake from a key biologics client and forex hedge losses
  - Partly offset by cost optimization initiatives

- **Strengthening Capabilities**
  - Strategic collaboration with BRIC-THSTI* enhances translational research and clinical development capabilities
  - Continued investment in Syn.AI@, digital technologies and emerging modalities

- **Outlook**
  - FY27 to be a transition year, with performance improving in 2H
  - New management team focused on sharpening commercial execution, strengthening delivery and building a more agile, cost-competitive organisation
  - Positioned for a return to sustainable growth from FY28

In ₹ Cr	Q1 FY27	Q1 FY26	Q4 FY26	YoY%	QoQ%
Segment Revenue	736	875	1,037	*(16)*	*(29)*
EBITDA	116	224	326	*(48)*	*(64)*
% of Revenue	*15%*	*25%*	*31%*		

**Biotechnology Research & Innovation Council - Translational Health Science and Technology Institute; @Syngene's AI-enabled scientific platform for accelerating drug discovery services*

Concluding Remarks

Concluding Remarks: Q1 FY27

- **Growth Momentum Building**
  - Recent launches and expanded manufacturing capacity support the next phase of growth
  - Performance expected to strengthen through FY27, led by Biosimilars
- **Translating Scale into Returns**
  - Focused on improving margins, free cash flow generation and RoCE
  - Generics profitability showing early benefits of operating leverage and fiscal prudence
- **Positioned for Sustainable Value Creation**
  - Integrated portfolio and global capabilities position us well for future opportunities
  - Committed to translating growth into stronger earnings and shareholder value

SCIENCE FOR PEOPLE
ADVANCING IMPACT

Q&A